rs its advanced microbiome technology, called RapidAIM, to enable drug discovery, compound screening and to support the development needs of pharmaceutical and biotech companies.
- focuses on screening compounds against individual microbiomes (human and animals).
- develops compound libraries that can reach the gut microbiome.
- provides industry-leading functional metaproteomics, metagenomics and metabolomics approaches.
- provides leading bioinformatics and software tools to assess the effects of drugs on the microbiome.
For more information about MedBiome and interests in collaborations Please contact us at:email@example.com